2020 Avon Court, #4
Charlottesville, VA 22902
434-220-0718
info@diffusionpharma.com
 RSS Feed
  • Home
  • About Us
    • Company History
    • Leadership Team
      • Management Team
        • David Kalergis, JD/MBA
        • John L. Gainer, PhD
        • Matthew W. Hantzmon, MBA
        • Ben Shealy, MBA/CFA
        • David R. Jones, M.D., Chief Scientific Officer
        • Kim Whitten, PharmD, RAC
        • Robert Murray, PhD
        • James Edward John, III
        • Kelly Hoy
        • Tracey Linkous Danner, CTM
      • Board of Directors
        • David Kalergis, JD/MBA
        • John L. Gainer, PhD
        • Mark T. Giles, JD
        • Thomas Byrne, JD
        • Robert W. Adams, JD
      • Scientific Advisory Board
        • John L. Gainer, PhD
        • Stuart A. Grossman, MD
        • John A. Jane, Sr., MD, Ph.D., FRCS(C), FACS
        • David R. Jones, M.D.
        • Guy M. Chisolm, Ph.D.
    • Patent Portfolio
    • News
      • Press Releases
      • Subscribe to our news
      • Key Contacts
    • Contact Us
    • Directions
  • Business Development
  • Investors
  • Pipeline
    • Patient Populations
    • Clinical Development of TSC
  • Science
    • Hypoxia and Hypoxic Conditions
    • Published Research
    • Our Scientific Collaborators

Accredited Investors

Accredited investors include those who are:

  • A natural person whose individual net worth, or joint net worth with a spouse, at the time of his or her purchase exceeds $1,000,000;
  • A natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with their spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year;
  • A trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring Units in Diffusion Pharmaceuticals LLC and whose purchase is directed by a sophisticated person as described in Regulation D;
  • An entity in which all of the equity owners are accredited investors under Section 6 of Diffusion Pharmaceuticals’ Subscription Agreement; or
  • An entity not formed for the purpose of investing in the Company with total assets in excess of $5,000,000.

If you are an accredited investor and are interested in learning more about the company and potentially investing in Diffusion, please contact us via this form:

Request for Investor Information

*



*





*



*



*

*



*


* required



Home | About Us | Business Development | Investors | Pipeline | Science


BioNetwork East - Investment Challenge Winner

©2010 Diffusion Pharmaceuticals LLC
Terms of Use